Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00531284 · OUTCOME

Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma · Source last updated 2017-08-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
hours
Interval / dispersion
Standard Deviation
Time frame
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

Analysis population: Safety population with available pharmacokinetic (PK) data. PK analyses were conducted in solid tumor and multiple myeloma groups only and were not conducted for lymphoma or participants enrolled under Amendment 4 (CFX + dexamethasone).

Groups in this outcome

ST: CFZ 20 mg/m² Bolus

Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Day 1.

ST: CFZ 20 mg/m²

Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Day 1.

ST: CFZ 36 mg/m²

Participants with solid tumors received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Day 1.

ST: CFZ 45 mg/m²

Participants with solid tumors received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Day 1.

MM: CFZ 20 mg/m²

Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Day 1.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ST: CFZ 20 mg/m² Bolus23
ST: CFZ 20 mg/m²18
ST: CFZ 36 mg/m²6
ST: CFZ 45 mg/m²6
MM: CFZ 20 mg/m²27

Reported measurements

Source class 1
Values in hours · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
ST: CFZ 20 mg/m² Bolus0.09020.0319Not reportedNot reportedNot reported
ST: CFZ 20 mg/m²0.2270.150Not reportedNot reportedNot reported
ST: CFZ 36 mg/m²0.1160.0828Not reportedNot reportedNot reported
ST: CFZ 45 mg/m²0.2050.156Not reportedNot reportedNot reported
MM: CFZ 20 mg/m²0.1170.0799Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.0319
        value
        0.0902
      2. group Id
        OG001
        spread
        0.150
        value
        0.227
      3. group Id
        OG002
        spread
        0.0828
        value
        0.116
      4. group Id
        OG003
        spread
        0.156
        value
        0.205
      5. group Id
        OG004
        spread
        0.0799
        value
        0.117
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    2. group Id
      OG001
      value
      18
    3. group Id
      OG002
      value
      6
    4. group Id
      OG003
      value
      6
    5. group Id
      OG004
      value
      27
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Day 1.
    id
    OG000
    title
    ST: CFZ 20 mg/m² Bolus
  2. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Day 1.
    id
    OG001
    title
    ST: CFZ 20 mg/m²
  3. description
    Participants with solid tumors received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Day 1.
    id
    OG002
    title
    ST: CFZ 36 mg/m²
  4. description
    Participants with solid tumors received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Day 1.
    id
    OG003
    title
    ST: CFZ 45 mg/m²
  5. description
    Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Day 1.
    id
    OG004
    title
    MM: CFZ 20 mg/m²
param Type
MEAN
population Description
Safety population with available pharmacokinetic (PK) data. PK analyses were conducted in solid tumor and multiple myeloma groups only and were not conducted for lymphoma or participants enrolled under Amendment 4 (CFX + dexamethasone).
reporting Status
POSTED
time Frame
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
title
Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib
type
SECONDARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice